Disulfide Bond-Responsive Nanotherapeutic Systems for the Effective Payload in Cancer Therapy.
Disulfide bonds
cross-linked polymers
glutathione
redox-responsive drug delivery
systems
reduction responsiveness
tumor tissue
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
03
2020
accepted:
28
06
2020
pubmed:
8
7
2020
medline:
27
4
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
The progressive treatment of cancer using disulfide bond-based therapeutics offers improvement in therapeutic potency of active, reduction in adverse events, prolongation of drug release pattern and on-site action by interacting with neoplastic cell microenvironment. The objective of this article is to highlight the research carried out on disulfide bond-based drug delivery systems as a potential candidate for cancer treatment. The article provides an overview of the importance of disulfide bonds in cancer treatment in terms of their properties, mechanism of formation/fragmentation and applications. Properties of disulfide bonds, such as pKa, entropy, and dihedral angle contribute to the structural stability of the bonds in a nanotherapeutic system, while their formation and fragmentation are attributed to the presence of a high concentration of GSH in cancer cells. The article further focuses on various drug delivery systems like dendrimers, liposomes, micelles, etc. involving disulfide cross-linked polymers for the preparation of redox-responsive drug delivery systems. The use of nanotechnology with disulfide bond creates an anticancer drug delivery system with higher target specificity, improved bioavailability, and good therapeutic efficacy. In the near future, the combination of DSB with active, cellular material, stem cell and biological fluid will be considered as a new thrust area for research in healthcare.
Sections du résumé
BACKGROUND
The progressive treatment of cancer using disulfide bond-based therapeutics offers improvement in therapeutic potency of active, reduction in adverse events, prolongation of drug release pattern and on-site action by interacting with neoplastic cell microenvironment.
OBJECTIVE
The objective of this article is to highlight the research carried out on disulfide bond-based drug delivery systems as a potential candidate for cancer treatment.
METHODS
The article provides an overview of the importance of disulfide bonds in cancer treatment in terms of their properties, mechanism of formation/fragmentation and applications. Properties of disulfide bonds, such as pKa, entropy, and dihedral angle contribute to the structural stability of the bonds in a nanotherapeutic system, while their formation and fragmentation are attributed to the presence of a high concentration of GSH in cancer cells. The article further focuses on various drug delivery systems like dendrimers, liposomes, micelles, etc. involving disulfide cross-linked polymers for the preparation of redox-responsive drug delivery systems.
RESULTS
The use of nanotechnology with disulfide bond creates an anticancer drug delivery system with higher target specificity, improved bioavailability, and good therapeutic efficacy.
CONCLUSION
In the near future, the combination of DSB with active, cellular material, stem cell and biological fluid will be considered as a new thrust area for research in healthcare.
Identifiants
pubmed: 32634075
pii: CPD-EPUB-107956
doi: 10.2174/1381612826666200707131006
doi:
Substances chimiques
Disulfides
0
Drug Carriers
0
Liposomes
0
Micelles
0
Polymers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5353-5361Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.